Keyword: Sage Therapeutics
In response to declining venture investment in some disease areas, BIO is releasing reports to identify barriers to innovation.
SAGE-217 triggered near-immediate, fairly durable improvements in patients with major depressive disorder.
The trials linked the drug to improvements on a depression scale, teeing Sage up to file for approval next year and sending its stock up 44%.
Kerrisdale Capital Management, known for its activist short positions, has given Prothena the unwanted title of the “next big biotech blowup.”
Sage Therapeutics has posted a late-stage failure for brexanolone.
Sage Therapeutics posted phase 2 results from its Parkinson’s disease study yesterday in which it said its experimental med could help tremors, but the top-line data were met with confusion by Bio Twitter, and its shares fell more than 3% in normal hours trading.
In an interview with Bloomberg published yesterday, Sage CEO Jeff Jonas was quoted as saying his company was at the top of everyone’s buying list, sending its shares jumping, But a few short hours later (and just before the end of after-hours trading), the chief rowed back on the M&A talk.
Sage Therapeutics was up 35% in early trading on positive top-line Phase II data to treat severe postpartum depression.